Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IVIG for COVID-19-induced cytokine storm
IRCT20200317046797N3Phase 3Completed
- Sponsor
- Tabriz University of Medical Sciences
- Start
- Apr 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of immune globulin in coronavirus disease 2019 (COVID-19) and coronavirus pneumonia (2 arms), sponsored by Tabriz University of Medical Sciences. Primary endpoints: Change in pneumonia severity on CT scan, Hospitalization period and 4 more. Started Apr 2020; status: completed.
02
Drugs
immune globulin
03
Conditions
coronavirus disease 2019 (COVID-19)coronavirus pneumonia
Beyond the preview
Go deeper on IRCT20200317046797N3.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200317046797N3.